Suppr超能文献

严重持续性血小板减少症患者经导管主动脉瓣植入术的安全性和可行性

Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia.

作者信息

Fox Henrik, Hemmann Katrin, Doss Mirko, Beiras-Fernandez Andres, Zeiher Andreas M, Moritz Anton, Fichtlscherer Stephan, Lehmann Ralf

机构信息

aDepartment of Cardiology bDepartment of Heart Surgery, Johann Wolfgang Goethe-University Frankfurt, Frankfurt, Germany.

出版信息

Blood Coagul Fibrinolysis. 2013 Oct;24(7):732-5. doi: 10.1097/MBC.0b013e3283626252.

Abstract

Untreated symptomatic high-grade aortic stenosis remains a lethal disease. Therefore, a comprehensive evaluation is necessary to obtain the best individual treatment for each patient. Recently, transcatheter aortic valve implantation (TAVI) was developed as an innovative therapy for high-risk and inoperable patients. Persistent thrombocytopenia is an established risk for conventional open heart surgery, but is not covered by traditional surgical risk scores. The aim of the study was the investigation of safety and feasibility of TAVI in patients with severe thrombocytopenia. Because of the complicated outcome of patients with persistent thrombocytopenia undergoing heart surgery, we considered all patients with high-grade aortic stenosis and a thrombocyte count of less than 100 per nl as surgical high-risk patients. Out of these high-risk surgical patients, six patients with symptomatic high-grade aortic stenosis and severe thrombocytopenia were deemed to be TAVI candidates and underwent TAVI procedures in 2010 and 2011 (transfemoral: n = 4; transapical: n = 2) at the University Hospital of Frankfurt. The outcome of these patients was analyzed prospectively in order to document safety and feasibility of TAVI in such patients. All TAVI procedures were performed successfully with excellent functional results. There was no occurrence of major or minor bleeding complications, acute renal failure or nosocomial infection. One patient died of an ischemic stroke 12 days after the procedure. The five remaining patients were alive at the 12-month follow-up without relevant cardiovascular events and excellent valve performance. TAVI is an effective and well tolerated method to treat patients with chronic persistent thrombocytopenia and symptomatic high-grade aortic stenosis, and therefore a reasonable alternative to conventional heart surgery in such patients. The indication for TAVI in patients with thrombocytopenia and symptomatic high-grade aortic stenosis might be generated independently from conventional scoring systems.

摘要

未经治疗的有症状重度主动脉瓣狭窄仍然是一种致命疾病。因此,需要进行全面评估,以便为每位患者制定最佳个体化治疗方案。最近,经导管主动脉瓣植入术(TAVI)作为一种针对高危和无法手术患者的创新疗法得以发展。持续性血小板减少是传统心脏直视手术已明确的风险,但传统手术风险评分未涵盖这一点。本研究的目的是调查TAVI在重度血小板减少患者中的安全性和可行性。鉴于持续性血小板减少患者接受心脏手术的结果复杂,我们将所有重度主动脉瓣狭窄且血小板计数低于每微升100个的患者视为手术高危患者。在这些高危手术患者中,6例有症状的重度主动脉瓣狭窄且伴有严重血小板减少的患者被认为是TAVI候选者,并于2010年和2011年在法兰克福大学医院接受了TAVI手术(经股动脉:n = 4;经心尖:n = 2)。对这些患者的结果进行了前瞻性分析,以记录TAVI在此类患者中的安全性和可行性。所有TAVI手术均成功完成,功能结果良好。未发生大出血或小出血并发症、急性肾衰竭或医院感染。1例患者在术后12天死于缺血性卒中。其余5例患者在12个月随访时存活且无相关心血管事件,瓣膜功能良好。TAVI是治疗慢性持续性血小板减少和有症状重度主动脉瓣狭窄患者的一种有效且耐受性良好的方法,因此是此类患者传统心脏手术的合理替代方案。血小板减少和有症状重度主动脉瓣狭窄患者TAVI的适应证可能独立于传统评分系统而产生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验